|
|
|
|
 |
|
|
|
|
|
SUN-461, a soft steroid, is our lead for respiratory diseases such as asthma / COPD. SUN-461 is currently in preclinical studies. Like most medications used to treat asthma, the medication is designed to be delivered directly to the lungs by inhalation. Soft steroids are designed to maintain the anti-inflammatory properties of corticosteroids, while substantially reducing the potential for side effects. |
|
|
|
|
|
Soft corticosteroids are designed in such a manner that they undergo quick and easy metabolism just after they have acted, to produce inactive metabolites. This feature is built into the way the drug is designed, and indicates that the molecule will largely be devoid of the side effects that limit the use of steroids. |
|
|
|
|
| |
| In animal studies, SUN-461 was found to be as effective as currently marketed steroids like ciclesonide, budesonide and fluticasone. Unlike classical steroids, our compound does not lower overall immune system in animal models, and shows reduced or no interference with the mechanism for glucose metabolism. |
|
| Previously, in preclinical studies, SUN-461 had shown anti-inflammatory activity comparable to currently marketed steroids. In in vitro studies, |
|
 |
|
|
the compound showed selective and potent binding to glucocorticoid receptors, with insignificant binding to mineralocorticoid and related steroid hormone receptors. |
|
|
|
|
|
The molecule has been screened in disease models for asthma such as eosinophilia and TNF-< in sensitized animals. In sub acute toxicity studies, SUN- 461 had a good safety profile. |
|
|
|
|
